Latest news with #UmangVohra
Mint
14-05-2025
- Business
- Mint
Stocks to watch: Bharti Airtel, Tata Motors, HAL, Cipla among shares in focus today
Shares of HAL, Tata Power, Eicher Motors and Jubilant Food are expected to be in the spotlight today as these companies are set to release their fourth-quarter earnings. Bharti Airtel reported a significant year-on-year increase of 432% in its net profit, reaching ₹ 11,022 crore for the fourth quarter. However, the company noted that after adjusting for exceptional items, the profit grew 77% YoY to ₹ 5,223 crore. Tata Motors, a leading automobile manufacturer, reported a 51% decline in its consolidated net profit, which stood at ₹ 8,470 crore for the quarter ending March 2025. Bharti Hexacom posted a 79% quarter-on-quarter increase in net profit, reaching ₹ 468 crore in the fourth quarter, while its revenue from operations rose by 2% to ₹ 2,289 crore. The Defence Public Sector Undertaking (PSU) reported a 118.9% year-on-year increase in net profit, reaching ₹ 244.2 crore for the fourth quarter ending March 31, 2025. Life Insurance Corporation (LIC) has increased its shareholding in Bank of India (BoI) to 8.38% as of May 9. Tata Steel has allocated ₹ 15,000 crore for capital spending across its operations in India, the UK, and the Netherlands for the current financial year. Aditya Birla Capital reported a net profit of ₹ 654 crore for the fourth quarter, with net interest income totaling ₹ 1,800 crore. Umang Vohra, the Managing Director and Global CEO of Cipla, stated that the US government's directive for pharmaceutical companies to reduce prescription drug prices within 30 days will not affect Indian generic drug manufacturers. The diagnostics chain reported a 19.4% decrease in its Q4 net profit, totaling ₹ 29 crore, compared to ₹ 36 crore in Q4FY24. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
14-05-2025
- Business
- Time of India
Stocks in news: HAL, Eicher Motors, Airtel, Tata Motors, Cipla
Markets took a breather after a strong start to the week, ending Tuesday's session with a loss of over one percent. In today's trade, shares of HAL , Eicher Motors , Airtel , Tata Motors , Cipla among others will be in focus due to various news developments and fourth quarter results. HAL, Eicher Motor, Tata Power, Shree Cements, Jubilant Food Shares of HAL, Eicher Motor, Tata Power, Shree Cements and Jubilant Food will be in focus as the companies will announce their fourth quarter results today. Tata Motors Leading automaker Tata Motors reported 51% fall in its consolidated net profit at Rs 8470 crore in the quarter ended March 2025. Bharti Airtel Bharti Airtel posted strong growth of 432% YoY in its net profit at Rs 11,022 crore in the fourth quarter. The company, however said, profit adjusted for exceptional items rose 77% YoY to Rs 5,223 crore. Metropolis Healthcare Metropolis Healthcare reported 19% decline in its net profit at Rs 29 crore while revenues were up 4% at Rs 345 crore in the fourth quarter. Bharti Hexacom Bharti Hexacom reported 79% sequential growth in its net profit at Rs 468 crore in the fourth quarter, while revenue from operations improved 2% at to Rs 2,289 crore. Aditya Birla Capital Aditya Birla Capital posted a net profit of Rs 654 crore in the fourth quarter, while net interest income came in at Rs 1800 crore. Tata Steel Tata Steel has earmarked a capital expenditure of Rs 15,000 crore for its operations in India, the UK and the Netherlands in the current financial year. Bank of India Life Insurance Corporation (LIC) has hiked its stake in Bank of India (BoI) to 8.38% as of May 9. Cipla The US government's order to pharma firms to lower the cost of prescription medicines within 30 days will not impact Indian generic drugmakers, Cipla MD and Global CEO Umang Vohra said.
&w=3840&q=100)
Business Standard
13-05-2025
- Business
- Business Standard
Cipla Q4FY25 results: Net profit zooms 30% to ₹1,221 cr, revenue up 9%
Cipla on Tuesday reported a 30 per cent year-on-year (Y-o-Y) growth in its consolidated net profit at ₹1221 crore for Q4FY25, while revenue from operations during the period grew by 9 per cent to ₹6,729 crore. For FY25, Cipla recorded its highest ever net profit which surged by 27.9 per cent Y-o-Y, reaching to ₹5,272 crore compared to ₹4,121 crore in FY24. Revenue from operations also grew by 6.8 per cent, reaching ₹27,547 crore, an increase from ₹25,774 crore in increase in the net profit for the year was attributed to good performance in all key markets including India, the US, South Africa, and Europe along with a robust product mix and operation efficiencies. Sequentially, revenue from operations dropped by 4.8 per cent, with the PAT also declining by 22.2 per cent. The firm's stock rose by 0.49 per cent to ₹1,519.45 a piece on the BSE. Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent. Umang Vohra, MD and Global CEO, Cipla, stated 'In FY25, we recorded a revenue growth of 8 per cent over last year with the Ebitda margin of 25.9 per cent, driven by mix and other operational efficiencies. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipelines as well as focusing on resolutions on the regulatory front.'
Time of India
13-05-2025
- Business
- Time of India
Cipla reports 30% increase in net profit, revenue up 9%
Cipla reports 30% increase in net profit, revenue up 9% NEW DELHI: Mumbai-based Cipla has reported a 30% year-on-year (YoY) increase in net profit, standing at Rs 1,222 crore for the fourth quarter ended March 31. The company's revenue was Rs 6,730 crore, reflecting a 9% growth from the corresponding period last year. For FY25, Cipla's revenue rose 8% to Rs 27,548 crore. Umang Vohra, MD and Global CEO, Cipla, commented on the implications of recent US policies in a post results' call, stating, 'We don't see any material impact of tariffs on generics as of now.' Regarding Trump's executive order announced on May 12, he noted, 'as of now, we understand that it's largely targeted at branded drugs. From a generic perspective, generic prices in the US are already significantly comparable with the rest of the world, and even lower in some cases.' Elaborating on the company's performance, he said, 'I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in branded prescription business continued to outpace the market growth, trade generics business growth trajectory is back on track and anchor brands of consumer health business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $934 million. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
13-05-2025
- Business
- Time of India
US govt order to have nil impact on Indian pharma players, says Cipla
Umang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug prices are already competitive. Vohra also states that potential US tariffs on pharmaceutical imports are not expected to significantly impact Cipla's business. He mentions that discussions between the US and Indian governments are ongoing. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The US government's order to pharma firms to lower the cost of prescription medicines within 30 days will not impact Indian generic drugmakers, Cipla MD and Global CEO Umang Vohra said on Tuesday. He noted that the Executive Order signed by US President Donald Trump on Monday is probably going to impact branded drugs."What we understand is that this is largely targeted towards branded of now, what we understand is that this is a voluntary measure that perhaps the companies will be taking," Vohra noted that there are aspects of MFN clauses etc and it is not clear as of now how and in which manner the Executive Order will be implemented."So as of now, from a generic perspective, I think generic (drug) prices in the US are already significantly comparable with the rest of the world, in some cases it is lower. So we don't believe that at least for now, based on what the promulgation says we think this is more (towards) branded anything on the generic side," Vohra May 12, Trump signed an executive order setting a 30-day deadline for drugmakers to lower the cost of prescription drugs in the order calls on the health department to broker new price tags for drugs. If a deal is not reached, a new rule will kick in that will tie the price of what the US pays for medications to lower prices paid by other to a query regarding the impact on the company's business if the US government imposes tax on pharmaceutical imports, Vohra said: "Our business continues as usual. There's never been any stoppage at any place in the US on account of any confusion with respect to tariffs."And so we don't see the impact. In any case, we are in the generic sector. The purpose of what we do is to provide medicines to people who really need it from an affordability perspective. So as of now, we don't see any impact of tariffs on our business," he noted that a lot is going to happen between the US government and the Indian government."We are monitoring all of that. And you know, we don't expect material changes to the business environment for generics," he noted that even if the Trump administration brings in the tariffs, it is going to be significantly lower than the other regular goods."I don't think there's one answer on whether everything will be passed on to the customers or everything will be absorbed. I think it's going to be a combination of the two," Vohra currently levies about 10 per cent import duty on American drugs while no charges are levied on Indian drugs being imported by the Trump administration is likely to impose tariffs on drug imports into the US in the days to April, the US government exempted the Indian pharma sector from reciprocal tariffs, recognising the vital role played by the domestic industry in supplying affordable medicines across the globe.
